A Phase 1/2 interventional study of TO-O-1007 (low-dose) and TO-O-1007 (high-dose) in Geographic Atrophy Due to Age-Related Macular Degeneration, sponsored by Theratocular Biotek Co.. Recruiting at 3 sites in Australia. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by Theratocular Biotek Co. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Geographic Atrophy with a site in Australia — 12 open to participants now, 15 under way, 4 of them phase 3. Geographic Atrophy · Australia.
Among the 41 studies in Geographic Atrophy with a site in Australia, this one is the 32nd largest by planned enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2026, is one of 4 in phase 1/2, reaches primary completion later than 4 of the 14 other live ones, and was the 41st registered.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
Browse Geographic Atrophy studies →12 of the 41 studies in Geographic Atrophy with a site in Australia are open now. Recruiting first, the newest first:
Biojiva LLC · Sites in Australia, United States
Ages 55+
Sitala Bio LTD · Sites in Australia, United States, Argentina and 4 more countries
Ages 60+
Novartis Pharmaceuticals · Sites in Australia, United States, Argentina and 16 more countries
Ages 50+
ADARx Pharmaceuticals, Inc. · Sites in Australia, United States, Austria and 9 more countries
Ages 60+
Sanofi · Sites in Australia, United States, United Kingdom
Ages 60+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 41 Geographic Atrophy studies recruiting now, 32 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 14 · Phase 4 1
First in 2014; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 31 is below the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Median enrollment 280 across the 34 interventional studies, 255 across the 7 observational. Of the 24 that completed or were terminated, 17 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 41 have an industry lead sponsor. The 10 most frequent:
Theratocular Biotek Co. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Theratocular Biotek Co. has 1 study filed under Geographic Atrophy — fewer than ten, so there is no comparison to draw.
6 of the studies in Geographic Atrophy with a site in Australia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05949593Phase 3Belite Bio, IncPhase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy | 2027-06-30 |
| NCT06510816Phase 3Annexon, Inc.A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | 2027-07-31 |
| NCT06662162i-Lumen Scientific AUS PTY LTDMicrocurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration | 2027-03-31 |
| NCT07668804Theratocular Biotek Co.A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy | 2027-08-31 |
| NCT06087458Perceive Biotherapeutics, Inc.Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration | 2027-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 41 studies in Geographic Atrophy with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of TO-O-1007, a biodegradable sustained-release intravitreal implant, for the treatment of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). A long-acting intravitreal implant providing sustained delivery of API over 6 months may slow the progression of GA lesions while reducing treatment burden associated with frequent intravitreal injections. TO-O-1007 may offer a convenient treatment option with the potential to preserve retinal structure and visual function while maintaining an acceptable safety profile.
TO-O-1007 is a biodegradable sustained-release intravitreal implant, that is injected into the vitreous cavity of the eye. The implant is designed to gradually degrade over time, providing sustained ocular delivery of API for up to 6 months following a single administration. By continuously inhibiting C3/C5 activation, TO-O-1007 is intended to slow the progression of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD), with the goal of preserving retinal structure and visual function. In this study, TO-O-1007 will be evaluated for its safety, tolerability, pharmacokinetics, and preliminary efficacy to determine whether it may offer a durable treatment option that reduces treatment burden compared with currently available therapies requiring more frequent intravitreal injections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 participants will receive TO-O-1007 (low-dose)
Drug: TO-O-1007 (low-dose)
3 participants will receive TO-O-1007 (high-dose)
Drug: TO-O-1007 (high-dose)
10 participants will receive TO-O-1007 (low-dose)
Drug: TO-O-1007 (low-dose)
10 participants will receive TO-O-1007 (high-dose)
Drug: TO-O-1007 (high-dose)
5 participants will receive a sham injection.
Procedure: Sham injection
TO-O-1007 (low-dose): Participants will receive one TO-O-1007 implant administered by intravitreal injection into the study eye.
TO-O-1007 (high-dose): Participants will receive two TO-O-1007 implants administered by intravitreal injection into the study eye.
Sham injection: No injection is given. It is a sham injection to keep the participant masked.
Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
Number and percentage of participants experiencing at least one treatment-emergent adverse event, including serious adverse events and adverse events of special interest.
Time frame: Up to 6 months treatment duration
Geographic Atrophy Lesion Growth
Change in the growth rate of square root-transformed total Geographic Atrophy lesion area in the study eye, assessed by fundus autofluorescence (FAF) imaging through Week 24.
Time frame: Baseline, Week 12, and Week 24.
Visual Function Assessments
Mean change from baseline in BCVA, LL-BCVA, and low-luminance deficit (LLD), assessed using ETDRS charts under photopic and low-luminance conditions through Week 24.
Time frame: Week 12 and Week 24.
Exposure endpoint (only for phase I)
Plasma concentrations of TO-O-1007
Time frame: Day 1 pre-dose, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 28 post first dosing.
Started Jun 2026 (actual). Primary completion is estimated for Aug 2027, 14 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Theratocular Biotek Co.